» Articles » PMID: 26543810

Levetiracetam-induced Rage and Suicidality: Two Case Reports and Review of Literature

Overview
Specialty Psychology
Date 2015 Nov 7
PMID 26543810
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Levetiracetam-induced rage is a rare neurobehavioral adverse effect of levetiracetam that is characterized by seething rage, uncontrollable anger, fits of fury, depression, violence, and suicidal tendencies. It occurs more in patients with prior mood or psychotic disturbances. No such case has been reported in Nigeria.

Method: We report two cases of levetiracetam-induced rage. The first patient was a 29-year-old male with a 14-year history of intractable posttraumatic epilepsy. He was initially placed on sodium valproate and phenobarbitone and later had phenobarbitone replaced with levetiracetam. Within the first week of initiating levetiracetam, he became aggressive, bursted into fits of fury, and attacked his siblings. Levetiracetam was stopped, and the seething rage ceased only to reappear when it was reintroduced; hence, the complete withdrawal of levetiracetam. Naranjo probability score for adverse drug reaction was 8.

Results: The second patient was a 23-year-old lady who developed seething rage and made several attempts to kill herself with a knife following addition of levetiracetam to the clonazepam and carbamazepine that she was taking for treatment-resistant epilepsy. Withdrawal and reintroduction of levetiracetam by the relatives led to cessation and reemergence, respectively, of the rage and suicidal tendencies. Naranjo score was 8. Levetiracetam was discontinued.

Conclusion: Neuropsychiatric evaluation for prior mood or psychiatric disorders in those initiating levetiracetam therapy is suggested alongside monitoring for early features of levetiracetam-induced rage by both caregivers and physicians. This will help stem the morbidity and potential mortality associated with this life-threatening adverse drug reaction.

Citing Articles

Unusual side effects of levetiracetam.

Badarny S, Badarny Y, Mihilia F BMJ Case Rep. 2021; 14(4).

PMID: 33906894 PMC: 8076925. DOI: 10.1136/bcr-2021-242496.


Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge.

Ogunsakin O, Tumenta T, Louis-Jean S, Mahbub A, Rabel P, Olupona T Case Rep Psychiatry. 2020; 2020:8883802.

PMID: 32908767 PMC: 7450317. DOI: 10.1155/2020/8883802.


Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Yi Z, - , Wen C, Cai T, Xu L, Zhong X Neuropsychiatr Dis Treat. 2018; 15:1-19.

PMID: 30587993 PMC: 6301299. DOI: 10.2147/NDT.S181886.


Levetiracetam Induced Neuropsychiatric Manifestation in a 5-year-old Boy.

M K, Dhawan S, Singanamala B, Saini L, Sahu J Indian J Pediatr. 2018; 86(2):193.

PMID: 30209735 DOI: 10.1007/s12098-018-2788-8.


Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders.

Tallian K Ment Health Clin. 2018; 7(6):235-245.

PMID: 29955529 PMC: 6007731. DOI: 10.9740/mhc.2017.11.235.

References
1.
Turner W . The Food and Drug Administration algorithm. Special workshop--regulatory. Drug Inf J. 1983; 18(3-4):259-66. DOI: 10.1177/009286158401800311. View

2.
Helmstaedter C, Fritz N, Kockelmann E, Kosanetzky N, Elger C . Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav. 2008; 13(3):535-41. DOI: 10.1016/j.yebeh.2008.05.012. View

3.
Lhatoo S, Johnson A, Goodridge D, MacDonald B, Sander J, Shorvon S . Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol. 2001; 49(3):336-44. View

4.
VanCott A, Cramer J, Copeland L, Zeber J, Steinman M, Dersh J . Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med. 2010; 8:4. PMC: 2823654. DOI: 10.1186/1741-7015-8-4. View

5.
Lee J, Song H, Hwang Y, Lee H, Suh C, Park S . Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J Clin Neurol. 2011; 7(3):128-36. PMC: 3212598. DOI: 10.3988/jcn.2011.7.3.128. View